Clinical Trial News and Research

RSS

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

Abbott announced today that the first patient in Japan has been treated with the ABSORB bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND clinical trial.

18 Aug 2011

NCRM at Case Western Reserve to host stem cell conference in Cleveland

The National Center for Regenerative Medicine (NCRM) at Case Western Reserve University is proud to present "MSC 2011: Innovations in Cell-Based Regenerative Therapies," a three-day forum to highlight transformative breakthroughs in the area of adult stem cell medicine with a focus on how this research is being applied in patient care settings through innovative clinical trials.

18 Aug 2011

Lighter smokers with two high-risk gene variations more likely to develop lung cancer

Smokers with variations in two specific genes have a greater risk of smoking more cigarettes, becoming more dependent on nicotine and developing lung cancer, a new study from the Centre for Addiction and Mental Health (CAMH) shows.

18 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Allos Therapeutics, Inc. today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma.

18 Aug 2011

New gout drug may help severely affected: Study

A new drug for gout could help very sick gout patients who don't get better with usual treatment, according to a new study. The research was designed and funded by the pharmaceutical company Savient, which markets the drug, called Krystexxa (pegloticase).

17 Aug 2011

Neovasc completes previously announced non-brokered private placement

Neovasc Inc. today announced that it has completed a previously announced non-brokered private placement of 4,720,500 equity units at the price of $1.00 per unit for aggregate gross proceeds of approximately $4,720,500.

17 Aug 2011

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

A CANCER RESEARCH UK-funded trial of a new drug for patients with advanced breast or ovarian cancer due to inherited gene faults has been launched at the Oxford Experimental Cancer Medicine Centre (ECMC) at the University of Oxford.

17 Aug 2011

GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

17 Aug 2011

Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

17 Aug 2011

LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease

LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.

16 Aug 2011

Gene therapy cocktail can treat inherited diseases with 'misfolded' proteins

In a kind of molecular gymnastics, scientists at the University of North Carolina at Chapel Hill School of Medicine have devised a gene therapy cocktail that has the potential to treat some inherited diseases associated with "misfolded" proteins.

16 Aug 2011

AVI BioPharma, MDA to initiate exon-51 Phase 2 trial in Duchenne muscular dystrophy

More than a decade of targeted Muscular Dystrophy Association-funded research, made possible as a result of generous public support of the MDA Labor Day Telethon and thousands of grass-roots special events, has today culminated in MDA providing financial assistance for the start of the first Phase 2 placebo-controlled, multiple dose efficacy, safety, tolerability and pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, as a potential therapy for Duchenne muscular dystrophy.

16 Aug 2011

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been enrolled in its ESPRIT Phase III clinical trial of Epanova, in patients with hypertriglyceridemia (TG level greater than or equal to 200 and < 500 mg/dL) despite treatment with a statin.

16 Aug 2011

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that the first patients have been enrolled and randomized to receive RGN-259 or placebo in its 72-patient, Phase 2 clinical trial in patients with dry eye syndrome.

16 Aug 2011

Starpharma starts bacterial vaginosis prevention study of VivaGel

Starpharma Holdings Limited today announced the commencement of its Phase 2 study of VivaGel for the prevention of bacterial vaginosis (BV), following receipt of ethics approval.

15 Aug 2011

Medgenics second quarter net loss increases to $2.32 million

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three and six months ended June 30, 2011.

12 Aug 2011

PLC Systems second quarter total revenues increase to $398,000

PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and six month periods ended June 30, 2011. These results only include the company's RenalGuard® operations, since PLC completed the sale of its transmyocardial revascularization (TMR) business to Novadaq Corp. during the first quarter of 2011.

12 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011

Clinical Trial News and Research

Abbott initiates ABSORB BVS device clinical trial in coronary artery disease

NCRM at Case Western Reserve to host stem cell conference in Cleveland

Lighter smokers with two high-risk gene variations more likely to develop lung cancer

CEL-SCI receives Chinese patent for Multikine cancer drug

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

New gout drug may help severely affected: Study

Neovasc completes previously announced non-brokered private placement

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program

Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial

LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease

Gene therapy cocktail can treat inherited diseases with 'misfolded' proteins

AVI BioPharma, MDA to initiate exon-51 Phase 2 trial in Duchenne muscular dystrophy

Enrollment commences in Omthera's Epanova Phase III trial for hypertriglyceridemia

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

Starpharma starts bacterial vaginosis prevention study of VivaGel

Medgenics second quarter net loss increases to $2.32 million

PLC Systems second quarter total revenues increase to $398,000

Galectin second quarter net loss increases to $3.9 million

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer